Lumateperone is the most recently approved FDA-approved medication for the treatment of schizophrenia. Watch the following short video discussion from our journal club regarding the likely mechanism of action for Lumateperone
LUMATEPERONE: MECHANISM OF ACTION
Watch our journal club for a detailed discussion on this topic:
Lumateperone for Treatment of Schizophrenia.
This journal club will be summarized in the following topics/questions:
- Lumateperone: Mechanism of action.
- Recommended dosage and titration.
- Lumateperone 28 mg vs 42 mg vs 84 mg: which one is preferred?
- When is the onset of response with Lumateperone?
- Lumateperone: Common adverse events.
- Association of Lumateperone with EPS, metabolic side effects, QTc prolongation and increase in suicidal ideations?
- How Lumateperone compares with other antipsychotics in terms of effect size for reduction in PANSS total symptoms?
WATCH JOURNAL CLUB:
FOR ACADEMY MEMBERS ONLY
INTERESTED IN LEARNING MORE?
JOIN PSYCHIATRY EDUCATION FORUM ACADEMY MEMBERSHIP
This is a closed membership for medical professionals only.
- 30+ Courses/Sections: Each chapter within these sections is of direct clinical relevance for your daily practice.
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice.
- Coffee Club: contain short discussions with clinical experts in the field of psychiatry.
- Essentials of Inpatient Psychiatry Book: All chapters from this book are included in the academy sections.
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases.
- Conference Discounts: Academy members get discounted access at our conferences.
- Goal: is to have all important clinically relevant topics in one place for ease of access.
SUBSCRIBE TO OUR EMAIL NEWSLETTER: